EGFR and head and neck squamous cell carcinoma: Targeted drugs, such as cetuximab, an epidermal growth factor receptor (EGFR)–specific antibody, have been utilized for HNSCC and reached a limited response rate, possibly due to its clinical heterogeneity (Licitra et al., 2011).